ArticlesRegression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study
Introduction
Progression to cirrhosis, development of hepatocellular carcinoma, and liver-related mortality are associated with persistent replication of hepatitis B virus (HBV) and high plasma HBV DNA concentrations in patients chronically infected with the virus.1, 2, 3 In an estimated 15–40% of patients with chronic HBV infection, progression to cirrhosis, liver failure, or hepatocellular carcinoma will occur.4 Worldwide, HBV infection accounts for about 50% of all cases of hepatocellular carcinoma, most of which (up to 80%) are in patients with cirrhosis.5 Viral suppression by means of inhibitors of HBV polymerase/reverse transcriptase has achieved clinical benefits with a reduction in hepatic decompensation and lower rates of hepatocellular carcinoma in cirrhotic patients.6, 7, 8 However, little is known about progressive changes in liver histology with long-term antiviral therapy. Advanced liver fibrosis was previously thought to be irreversible, but evidence is accruing that cirrhosis can be reversed if the underlying cause of liver injury is addressed.6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 The evidence of an association between suppression of HBV replication and regression of liver fibrosis has, however, come from small studies that were not controlled adequately for antiviral use or treatment duration.6, 8, 17, 18, 19, 20, 21, 22, 23
Tenofovir disoproxil fumarate (DF), a nucleotide analogue and potent inhibitor of HBV polymerase/reverse transcriptase, is approved for the treatment of HIV-1 and chronic HBV infections.24 Two international, multicentre, randomised, double-blind phase 3 studies (NCT00117676 and NCT00116805) compared the efficacy and safety of once-daily tenofovir DF versus once-daily adefovir dipivoxil for 48 weeks.25 Tenofovir DF was more effective than adefovir in terms of viral suppression and relief of histological inflammation.25 After week 48, patients continued on open-label tenofovir DF or were switched from adefovir to open-label tenofovir DF for a planned 7 further years.26 Participants in the open-label phase were eligible for a prespecified third liver biopsy at week 240. We report here the effects of 5 years of viral suppression on histology in liver fibrosis and cirrhosis in 348 patients who had evaluable histology at baseline and week 240.
Section snippets
Study setting and patients
Patients were recruited from May, 2005, to June, 2006.25 After the initial 48-week randomised, masked comparison of tenofovir DF with adefovir, patients with chronic HBV infection (positive or negative for HBeAg) were switched to open-label tenofovir DF. Patients gave written consent for the open-label phase at the time of initial consent for study participation. Detailed descriptions of the study populations, design, and methods have been reported previously.25, 26
Procedures
Clinical, laboratory, and
Results
Of 641 patients enrolled and treated in the randomised trial, 585 (91%) entered the open label phase. 489 (76%) remained in the study at year 5. 634 patients (99%) had evaluable liver biopsy samples at baseline, and 348 (54%) had both baseline and year 5 liver biopsy results (figure 1). Ishak scores were available at all three timepoints (baseline, year 1, and year 5) for 344 patients. At 5 years of treatment, 141 (22%) patients had no biopsy data available (figure 1), mainly because patients
Discussion
Treatment for chronic HBV infection aims to maximise viral suppression with the objectives of controlling liver fibrosis and preventing progression to clinical complications associated with hepatic decompensation and hepatocellular carcinoma. Little evidence has been available on the effect of long-term HBV suppression on liver histology. Our study, of a large cohort of patients with baseline, year 1, and year 5 liver biopsy samples, has shown that up to 5 years of treatment with tenofovir DF
References (34)
- et al.
Predicting cirrhosis risk based on the level of circulating hepatitis B viral load
Gastroenterology
(2006) - et al.
Risk and predictors of mortality associated with chronic hepatitis B infection
Clin Gastroenterol Hepatol
(2007) - et al.
Histological outcome during long-term lamivudine therapy
Gastroenterology
(2003) - et al.
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years
Gastroenterology
(2006) - et al.
Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C
Gastroenterology
(2002) - et al.
High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study
J Hepatol
(2009) - et al.
Three year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B
Gastroenterology
(2011) - et al.
Histological grading and staging of chronic hepatitis
J Hepatol
(1995) - et al.
HBV DNA replication mediated by cloned patient HBV reverse transcriptase genes from HBV genotypes A-H and its use in antiviral phenotyping assays
J Virol Methods
(2011) - et al.
Diagnosis and quantitation of fibrosis
Gastroenterology
(2008)
Ethnicity and body mass index are associated with hepatitis C presentation and progression
Clin Gastroenterol Hepatol
Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level
JAMA
Chronic hepatitis B
N Engl J Med
Hepatocellular carcinoma
N Engl J Med
Lamivudine for patients with chronic hepatitis B and advanced liver disease
N Engl J Med
Regression of hepatic fibrosis in hepatitis C with long-term interferon treatment
Dig Dis Sci
Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C
Ann Intern Med
Cited by (1412)
Risk Factors for Development of Cirrhosis in Chronic Viral Hepatitis B Patients Who Had Persistent Viral Suppression With Antiviral Therapy
2024, Journal of Clinical and Experimental HepatologyMitochondrial dysfunction: A promising therapeutic target for liver diseases
2024, Genes and DiseasesTIPS for Portal Hypertension in HCC With Tumour Invasion of the Portal Vein Trunk: Anecdote or Promise?
2024, Journal of Clinical and Experimental HepatologyRegression of Liver Fibrosis in Patients on Hepatitis B Therapy Is Associated With Decreased Liver-Related Events
2024, Clinical Gastroenterology and Hepatology